Search
Search results
193 results found
On demand therapy for Parkinson's disease patients: Opportunities and choices. Postgrad Med. 2021 Sep;133(7):721-727. doi: 10.1080/00325481.2021.1936087.
Hauser, RA, PA LeWitt, and CL Comella. 2021. “On Demand Therapy for Parkinson’s Disease Patients: Opportunities and Choices. Postgrad Med. 2021 Sep;133(7):721-727. Doi: 10.1080/00325481.2021.1936087.”. Postgrad Med.
A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson's Disease. Sensors (Basel). 2021 Aug 12;21(16):5437. doi: 10.3390/s21165437. PMID: 34450879.
Rupprechter, S, G Morinan, Y Peng, T Foltynie, K Sibley, RS Weil, LA Leyland, et al. 2021. “A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson’s Disease. Sensors (Basel). 2021 Aug 12;21(16):5437. Doi: 10.3390/S21165437. PMID: 34450879.”. Sensors (Basel).
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. J Parkinsons Dis. 2021;11(4):1663-1675. doi: 10.3233/JPD-212672. PMID: 34486986
Hauser, RA, N Hattori, H Fernandez, SH Isaacson, H Mochizuki, O Rascol, F Stocchi, et al. 2021. “Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, As Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. J Parkinsons Dis. 2021;11(4):1663-1675. Doi: 10.3233/JPD-212672. PMID: 34486986”. J Parkinsons Dis.
AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutions. 5:100115. doi: 10.1016/j.prdoa.2021.100115. eCollection 2021. PMID: 34888518.
Lew, MF, RA Hauser, SH Isaacson, D Truong, AT Patel, A Brashear, W Ondo, et al. 2021. “AbobotulinumtoxinA Provides Flexibility for the Treatment of Cervical Dystonia With 500 U/1 mL and 500 U/2 mL Dilutions. 5:100115. Doi: 10.1016/J.prdoa.2021.100115. ECollection 2021. PMID: 34888518.”. Clin Park Relat Disord.
Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review. Mov Disord Clin Pract 2020;7:250-266.
Wallace, DM, WK Wohlgemuth, LM Trotti, AW Amara, IA Malaty, SA Factor, S Nallu, L Wittine, RA Hauser, and DM Wall. 2020. “Practical Evaluation and Management of Insomnia in Parkinson’s Disease: A Review. Mov Disord Clin Pract 2020;7:250-266.”. Mov Disord Clin Pract.
Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease. BMC Neurol 2016:16:90.
Hauser, RA, J Slawek, Paolo Barone, Elisabeth Dohin, E Surmann, M Asgharnejad, and L Bauer. 2016. “Evaluation of Rotigotine Transdermal Patch for the Treatment of Apathy and Motor Symptoms in Parkinson’s Disease. BMC Neurol 2016:16:90.”. BMC Neurol.
Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies. Int J Neurosci 2016;126:942-6.
Hauser, RA, V Abler, E Eyal, and RE Eliaz. 2016. “Efficacy of Rasagiline in Early Parkinson’s Disease: A Meta-Analysis of Data from the TEMPO and ADAGIO Studies. Int J Neurosci 2016;126:942-6.”. Int J Neurosci.
Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data. J Med Econ 2016;19:515-25.
Francois, C, RA Hauser, S Aballea, J Dorey, E Kharitonova, and Arthur Hewitt. 2016. “Cost-Effectiveness of Droxidopa in Patients With Neurogenic Orthostatic Hypotension: Post-Hoc Economic Analysis of Phase 3 Clinical Trial Data. J Med Econ 2016;19:515-25.”. J Med Econ.
Seeberger LC, Hauser RA.Carbidopa levodopa enteral suspension. Expert Opin Pharmacother 2015;16:2807-17.
Seeberger, LC, and RA Hauser. 2016. “Seeberger LC, Hauser RA.Carbidopa Levodopa Enteral Suspension. Expert Opin Pharmacother 2015;16:2807-17.”. Expert Opin Pharmacother.